Abstract
Targeted gene therapy aims at achieving the expression of therapeutic transgenes in specific and restricted cell populations, thus sparing all other cells of the unwanted effects of the gene product. This strategy is particularly appealing for therapy of the central nervous system (CNS), where many different cell types exist, and where the inappropriate expression of a molecule can produce grave consequences. To accomplish the objectives of targeted gene therapy, two different approaches have been developed. The first one consists in creating vectors that will deliver the transgene exclusively to the selected cells, that is manipulating the transductional capacities of the vector, and the second one is based on the transcriptional properties of the transgene, so that it will only be expressed in cells where the appropriate transcriptional machinery is present. Reaching the goals of targeted gene expression will greatly increase the specificity and safety of gene therapy, thus getting us closer to the fulfillment of the expectations generated by this new branch of molecular medicine.
Keywords: promoter, viral vector, adenovirus, gene transfer, retrovirus, nervous system, transduction, gene transcription, gene therapy
Current Gene Therapy
Title: Gene Therapy Targeting in the Central Nervous System
Volume: 3 Issue: 2
Author(s): Jorge A. Benitez and Jose Segovia
Affiliation:
Keywords: promoter, viral vector, adenovirus, gene transfer, retrovirus, nervous system, transduction, gene transcription, gene therapy
Abstract: Targeted gene therapy aims at achieving the expression of therapeutic transgenes in specific and restricted cell populations, thus sparing all other cells of the unwanted effects of the gene product. This strategy is particularly appealing for therapy of the central nervous system (CNS), where many different cell types exist, and where the inappropriate expression of a molecule can produce grave consequences. To accomplish the objectives of targeted gene therapy, two different approaches have been developed. The first one consists in creating vectors that will deliver the transgene exclusively to the selected cells, that is manipulating the transductional capacities of the vector, and the second one is based on the transcriptional properties of the transgene, so that it will only be expressed in cells where the appropriate transcriptional machinery is present. Reaching the goals of targeted gene expression will greatly increase the specificity and safety of gene therapy, thus getting us closer to the fulfillment of the expectations generated by this new branch of molecular medicine.
Export Options
About this article
Cite this article as:
Benitez A. Jorge and Segovia Jose, Gene Therapy Targeting in the Central Nervous System, Current Gene Therapy 2003; 3 (2) . https://dx.doi.org/10.2174/1566523034578429
DOI https://dx.doi.org/10.2174/1566523034578429 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutical Potential of CB<sub>2</sub> Receptors in Immune-Related Diseases
Current Molecular Pharmacology Future Prospect of RNA Interference for Cancer Therapies
Current Drug Targets Oxidative Stress in Schizophrenia
Current Neuropharmacology Cdc25A Protein Phosphatase: A Therapeutic Target for Liver Cancer Therapies
Anti-Cancer Agents in Medicinal Chemistry Treatment of CNS Malignancies with a Recombinant Oncolytic Poliovirus
Drug Design Reviews - Online (Discontinued) Challenges and Opportunities in Molecular Imaging
Current Medical Imaging Glioblastoma Multiforme Formation and EMT: Role of FoxM1 Transcription Factor
Current Pharmaceutical Design Mitochondria-Targeting Anticancer Metal Complexes
Current Medicinal Chemistry Anti-Epidermal Growth Factor Receptor Antibodies in the Treatment of Metastatic Colorectal Cancer
Recent Patents on Anti-Cancer Drug Discovery New Use for Old Drugs? Prospective Targets of Chloroquines in Cancer Therapy
Current Drug Targets Oncogenic MicroRNA-27a is a Target for Genistein in Ovarian Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Novel Approaches to Cancer Therapy Using Oncolytic Viruses
Current Molecular Medicine Apoptosis Pathways and Neuroblastoma Therapy
Current Pharmaceutical Design TRAIL-Based Therapeutic Approaches for the Treatment of Pediatric Malignancies
Current Medicinal Chemistry Targeting Epigenetics in Nervous System Disease
CNS & Neurological Disorders - Drug Targets Tubulin Inhibitors: A Patent Survey
Recent Patents on Anti-Cancer Drug Discovery Andrographolide Inhibits Osteopontin Expression and Breast Tumor Growth Through Down Regulation of PI3 Kinase/Akt Signaling Pathway
Current Molecular Medicine The Synthesis and Use of Boronated Amino Acids for Boron Neutron Capture Therapy
Anti-Cancer Agents in Medicinal Chemistry Kisspeptin Mediated Signaling in Cancer
Current Topics in Medicinal Chemistry Therapeutic Potential of Perineural Invasion, Hypoxia and Desmoplasia in Pancreatic Cancer
Current Pharmaceutical Design